


A REVOLUTIONARY NEW TECHNOLOGY FOR ASSESSMENT OF BRAIN HEALTH

Based on over a decade of R&D and the largest available database of brain electrical-neural function and analytics, elmindA is mapping brain functions such as attention and memory, dedicated to revolutionizing brain health.



SALSS CONTACT

Arun Menawat
Chairman

arunmenawat@gmail.com
972-9-951-6476

www.elmindA.com

elminda Ltd.
14 Maskit Street POB# 12941 Herzliya,
4673314 Israel

1205 Milwaukee Ave, Suite 202
Glenview IL, 60025 USA

SALSS PRESENTING COMPANY | 2018

elminda

elminda Ltd | Private Company

Founded in 2006, elmindA is a mid-stage company, commercially launching its technology, which reveals an individual's unique brain electrophysiological signatures, to create objective measurements that can bring greater certainty to the diagnosis of brain disorders and injuries, and improve clinical treatment decision-making. elmindA has received \$50MM funding over three rounds at increasing valuations.

OUR PRODUCTS & SERVICES

BNA™ (Brain Network Analysis) is a clinical decision support, stand-alone software technology. CE marked and cleared for use by the US FDA and Israel's Ministry of Health, it assists the interpretations of evoked potential responses. BNA leverages machine-learning, advanced algorithms, and large-population databases to provide a revolutionary way to understand how the brain's neural networks are activated, and inform about brain function. BNA™ processes post-hoc neural patterns in the brain related to specific functions evoked by repeatable tasks to create high-resolution, three-dimensional representations of the functional neural pathways that are activated in response to those tasks. By comparing a patient's test results to their previous healthy-state baseline – or to a Reference Brain Network Model generated from an extensive population database – BNA can give physicians a unique perspective on brain function unavailable with traditional methods. BNA can also function as a turnkey solution for EEG/ERP based assessment technologies for pharma/academic clinical trials.

WHAT MAKES US UNIQUE

We have completed numerous clinical trials demonstrating the utility of our innovative BNA™ technology in both clinical setting as well as for drug development and research. In the process, we've received numerous honors and accolades from noted organizations such as the World Economic Forum.

These data-driven, evidence-based insights expand our knowledge of the body's most important organ, potentially helping medical professionals to make more informed decisions about patient care, while speeding the development of more effective drugs and treatment protocols in the future.

WHY YOU SHOULD MEET US

elminda is looking to build awareness of its technology offering within the medical community, and for potential partners. In anticipation of a potential listing within 1-3 years, the Company is seeking further capital, with use of funds to power a forthcoming launch.

KEY TEAM

Ronen Gadot, MBA

- CEO
- Formerly, executive positions with Applied Materials, Philips Electronics and SHL Telemedicine

Prof. Amir Geva

- Founder & CTO
- Prof. at BGU and Technion, head of the Biomedical Signal Processing & Pattern Recognition Laboratory, at BGU

Geri Katz

- CFO
- Vast experience as CFO of private and publicly traded companies including PowerDsine, as well as COO and CEO of private companies

Arun Menawat

- Chairman
- Accomplished history of executive leadership success in the healthcare industry
- Former President & CEO and Chairman of Novadaq Technologies Inc.

